Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity.
about
Effects of recombinant adenovirus-mediated expression of IL-2 and IL-12 in human B lymphoma cells on co-cultured PBMCHuman cytokine-induced killer cells have enhanced in vitro cytolytic activity via non-viral interleukin-2 gene transferClinical application of adoptive T cell therapy in solid tumorsAdoptive immunotherapy in postoperative hepatocellular carcinoma: a systemic reviewAdoptive immunotherapy with interleukin-2 & induced killer cells in non-small cell lung cancer: A systematic review & meta-analysisDendritic cells decreased the concomitant expanded Tregs and Tregs related IL-35 in cytokine-induced killer cells and increased their cytotoxicity against leukemia cells.Phase II clinical trial of ex vivo-expanded cytokine-induced killer cells therapy in advanced pancreatic cancer.Autologous cytokine-induced killer cell transfusion increases overall survival in advanced pancreatic cancer.Autologous transplantation of cytokine-induced killer cells as an adjuvant therapy for hepatocellular carcinoma in Asia: an update meta-analysis and systematic reviewCytokine-induced NK-like T cells: from bench to bedside.Cytokine-Induced Killer Cells As Pharmacological Tools for Cancer Immunotherapy.Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma.Use of reporter genes for optical measurements of neoplastic disease in vivoGlobal transcriptome-wide analysis of CIK cells identify distinct roles of IL-2 and IL-15 in acquisition of cytotoxic capacity against tumor.Anti-tumor effects of CIK combined with oxaliplatin in human oxaliplatin-resistant gastric cancer cells in vivo and in vitroA truncated human NKG2D splice isoform negatively regulates NKG2D-mediated function.Non-MHC-restricted cytotoxic cells: their roles in the control and treatment of leukaemias.Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 "super-stimulation".Growth of human colorectal cancer SW1116 cells is inhibited by cytokine-induced killer cells.Thymoglobulin, interferon-γ and interleukin-2 efficiently expand cytokine-induced killer (CIK) cells in clinical-grade cultures.Anti-leukemia effect of ex vivo expanded DNT cells from AML patients: a potential novel autologous T-cell adoptive immunotherapy.Cytokine-induced killer (CIK) cells in cancer immunotherapy: report of the international registry on CIK cells (IRCC).Increasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric cancer patients.Evaluation of tumor response to cytokine-induced killer cells therapy in malignant solid tumors.Purified anti-CD3 × anti-HER2 bispecific antibody potentiates cytokine-induced killer cells of poor spontaneous cytotoxicity against breast cancer cellsThe clinical effects of dendritic cell vaccines combined with cytokine-induced killer cells intraperitoneal injected on patients with malignant ascitesEffects of MICA expression on the prognosis of advanced non-small cell lung cancer and the efficacy of CIK therapyRapid tumor formation of human T-cell leukemia virus type 1-infected cell lines in novel NOD-SCID/gammac(null) mice: suppression by an inhibitor against NF-kappaBCIK cells from patients with HCC possess strong cytotoxicity to multidrug-resistant cell line Bel-7402/RCellular immunotherapy after autologous hematopoietic stem cell transplantation: experimental strategies and clinical experiences.Cytokine-induced killer cells co-cultured with dendritic cells loaded with the protein lysate produced by radiofrequency ablation induce a specific antitumor response.Synthetic peptide ligands of the antigen binding receptor induce programmed cell death in a human B-cell lymphoma.Current advances in T-cell-based cancer immunotherapyAdoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantationAdoptive Cell Therapy of Melanoma with Cytokine-induced Killer CellsImmunotherapy for hepatocellular carcinoma: From basic research to clinical use.Revving up Natural Killer Cells and Cytokine-Induced Killer Cells Against Hematological Malignancies.Sequential Cytokine-Induced Killer Cell Immunotherapy Enhances the Efficacy of the Gemcitabine Plus Cisplatin Chemotherapy Regimen for Metastatic Nasopharyngeal Carcinoma.Visualizing the kinetics of tumor-cell clearance in living animals.The therapeutic effect of cytokine-induced killer cells on pancreatic cancer enhanced by dendritic cells pulsed with K-ras mutant peptide
P2860
Q24793078-F6828BEF-1D59-4942-BA25-9C1DA06153E3Q24804905-84B40B29-A579-489A-B3EA-6437F817C059Q27011283-4A4A6AE2-386D-4075-8148-57854D6CA538Q27026977-9F3F5358-D972-4964-BB23-85EF5DB46135Q28072200-285B4A83-6ED6-45C0-87C0-90EB071D225FQ31157715-56E3E86E-CB11-46CF-858A-CA0249E8D749Q33415850-5460F09A-810B-4E3C-9222-EC4278ACA29BQ33429758-6B503A33-665A-4A0C-AA70-062D02F2032AQ33761739-C397930F-739A-4984-9916-48F0AC58FB94Q33762499-7374ED07-16DA-44C2-BCD8-7BE65AD14490Q33875615-F152050D-3533-4542-945A-699888C39949Q33881828-E4EE0689-D2E6-4457-8AE2-FB9B1574D427Q33995764-A89C00DA-F324-401D-83E5-9E441F629235Q34050208-66FFE583-FA5C-4FD7-AC57-33F7C14B5AEAQ34128227-527FE610-CBCE-4D45-81E9-1417AF5F57E8Q34146619-D6B49344-F85E-4A10-BEBA-5A24AA842E36Q34319345-6D88596D-8630-4516-BDDC-F812F13468FFQ34367252-F66AA4A3-13F5-43CA-B99D-9BCF37FFC387Q34382415-9EC5DE89-1682-424B-A962-EF44A19B68C0Q34419059-265EDE41-B349-44B6-9FBD-BF8FD32384DFQ34426965-D2BF9605-0042-4EF4-8663-4385203BCBC8Q34446934-A49B2900-6179-43A9-A2F3-A43D81BEB7BFQ34450648-A2E2F0F0-1558-425F-8B22-7A210E9612F0Q34635795-A7903569-5AAE-4092-AACF-A69D071EF028Q34643044-66015920-0067-425D-A069-1DCCE05C5C81Q34769958-5AA5A0B6-7B5F-4DF9-9A10-DB4A0CF5572BQ34918975-D3F4B055-2E25-46E8-8EB7-EFD4501E5838Q34975395-36275248-C320-4D3A-8E56-6DF0B6BAC299Q35045325-48ABA14C-9C90-4993-A40A-A4E07D0A7BB0Q35137164-B4BF80F7-4F19-4511-A59B-2BF03E69E073Q35167582-E8ABE82C-AC23-43FA-943A-011DDF57FB57Q35187131-DEE75638-9D0A-4CC0-AD84-20C9EF1825BCQ35215158-7D948240-2E71-4616-B1F0-3C2D00A62420Q35218943-F99766DB-3E78-430E-89B4-7E577A510E46Q35543911-05C1802C-1FF4-4348-840E-7A6FF2546792Q35567765-848F22F9-72AB-4334-AEC7-D8CD6F8A4B0EQ35600095-39B4F997-4BAC-482A-950F-AE1EFFA5278FQ35670921-602274DB-C742-4F74-A631-74EE4EB5270CQ35731839-3EB4E521-4054-4F94-AF76-F6F362C94E72Q35755295-7B241884-3317-48BE-9D3A-4CB632206895
P2860
Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity.
description
1991 nî lūn-bûn
@nan
1991 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1991 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
name
Use of a SCID mouse/human lymp ...... otent antitumor cell activity.
@ast
Use of a SCID mouse/human lymp ...... otent antitumor cell activity.
@en
Use of a SCID mouse/human lymp ...... otent antitumor cell activity.
@nl
type
label
Use of a SCID mouse/human lymp ...... otent antitumor cell activity.
@ast
Use of a SCID mouse/human lymp ...... otent antitumor cell activity.
@en
Use of a SCID mouse/human lymp ...... otent antitumor cell activity.
@nl
prefLabel
Use of a SCID mouse/human lymp ...... otent antitumor cell activity.
@ast
Use of a SCID mouse/human lymp ...... otent antitumor cell activity.
@en
Use of a SCID mouse/human lymp ...... otent antitumor cell activity.
@nl
P2093
P2860
P356
P1476
Use of a SCID mouse/human lymp ...... otent antitumor cell activity.
@en
P2093
I G Schmidt-Wolf
I L Weissman
R S Negrin
P2860
P304
P356
10.1084/JEM.174.1.139
P407
P577
1991-07-01T00:00:00Z